◎ Sugi Atlas

Atlas / Drug / Acetaminophen

Acetaminophen

drug
On this page

Also known as AbdineAcephenAcetaminophen component of allayAcetaminophen component of anexsiaAcetaminophen component of anoquanAcetaminophen component of apadazAcetaminophen component of bancapAcetaminophen component of bancap hcAcetaminophen component of bucetAcetaminophen component of butapapAcetaminophen component of co-gesicAcetaminophen component of codrixAcetaminophen component of combogesicAcetaminophen component of combogesic ivAcetaminophen component of darvocetAcetaminophen component of dhc plusAcetaminophen component of dolene ap-65Acetaminophen component of drixoral plusAcetaminophen component of duradyne dhc

Summary

Acetaminophen (CHEMBL112) is an approved small-molecule cyclooxygenase 2 inhibitor (ATC N02BE51) targeting PTGS1, PTGS2, and TRPV4; indicated across 119 conditions including arthritic joint disease and common cold.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: N02BE51 (+2 more)
  • Targets: 3 (PTGS1, PTGS2, TRPV4)
  • Indications: 119 conditions
  • Clinical trials: 966
  • Chemistry: 151.16 Da · C8H9NO2

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL112
NameAcetaminophen
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID1983
ChEBICHEBI:46195
ATCN02BE51, N02BE01, N02BE71
Molecular formulaC8H9NO2
Molecular weight151.16
InChIKeyRZVAJINKPMORJF-UHFFFAOYSA-N

SMILES: CC(=O)NC1=CC=C(C=C1)O

IUPAC name: N-(4-hydroxyphenyl)acetamide

ChEBI definition: A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.

Pharmacological roles (ChEBI): cyclooxygenase 2 inhibitor, cyclooxygenase 1 inhibitor, non-narcotic analgesic, antipyretic, non-steroidal anti-inflammatory drug, cyclooxygenase 3 inhibitor, hepatotoxic agent, ferroptosis inducer, geroprotector.

Other ChEBI roles (chemical / environmental): xenobiotic, environmental contaminant, human blood serum metabolite.

Also known as: Abdine, Acephen, Acetaminophen, Acetaminophen component of allay, Acetaminophen component of anexsia, Acetaminophen component of anoquan, Acetaminophen component of apadaz, Acetaminophen component of bancap, Acetaminophen component of bancap hc, Acetaminophen component of bucet, Acetaminophen component of butapap, Acetaminophen component of co-gesic

Patent coverage: 49,594 distinct patent families (157,242 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 157,110 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
PTGS1COX-1Inhibition3.940%P23219
PTGS2COX-2Inhibition4.590%P35354
TRPV4TRPV4Inhibition6.520.6%Q9HBA0

Broader ChEMBL bioactivity targets: 24 (assay-derived). Sample: Bromodomain-containing protein 4, Microtubule-associated protein tau, Thyrotropin receptor, Retinoic acid receptor gamma, Bile acid receptor, Carbonic anhydrase 2, Menin/Histone-lysine N-methyltransferase MLL, Carbonic anhydrase 13, Cytochrome P450 1A1, Carbonic anhydrase 7.

Bioactivity

ChEMBL activities: 12 potent at pChembl ≥ 5 of 31 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
TSHR6.8Potency158.5nMCHEMBL_ACT_3912776
MB5.64IC502300nMCHEMBL_ACT_13388541
CA125.39Ki4100nMCHEMBL_ACT_2572996
CA25.21Ki6200nMCHEMBL_ACT_15774628
CA25.21Ki6200nMCHEMBL_ACT_2172309
CA25.21Ki6200nMCHEMBL_ACT_2573068
CA35.15Ki7100nMCHEMBL_ACT_2573059
Q99N235.04Ki9230nMCHEMBL_ACT_2172320
CA75.04Ki9100nMCHEMBL_ACT_2573014
CA15Ki10000nMCHEMBL_ACT_15774639
CA15Ki10000nMCHEMBL_ACT_2172299
CA15Ki10000nMCHEMBL_ACT_2573077

Target pathways

Aggregated over 3 target gene(s): PTGS1, PTGS2, TRPV4.

Top Reactome pathways

11 total, by targets touching each:

PathwayTargetsGenes
Synthesis of Prostaglandins (PG) and Thromboxanes (TX)2PTGS1, PTGS2
COX reactions1PTGS1
Synthesis of 15-eicosatetraenoic acid derivatives1PTGS2
TRP channels1TRPV4
Interleukin-10 signaling1PTGS2
Interleukin-4 and Interleukin-13 signaling1PTGS2
Biosynthesis of DHA-derived SPMs1PTGS2
Biosynthesis of EPA-derived SPMs1PTGS2
Biosynthesis of DPAn-3 SPMs1PTGS2
Biosynthesis of electrophilic ω-3 PUFA oxo-derivatives1PTGS2
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells1TRPV4

Dominant GO biological processes

GO termTargets
prostaglandin biosynthetic process2
response to oxidative stress2
regulation of blood pressure2
cyclooxygenase pathway2
regulation of cell population proliferation2
long-chain fatty acid biosynthetic process2
lipid metabolic process2
fatty acid metabolic process2
fatty acid biosynthetic process2
prostaglandin metabolic process2
prostanoid biosynthetic process2
cellular oxidant detoxification2
embryo implantation1
response to nematode1
response to selenium ion1

Indications & clinical

Indications

119 indications (12 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
arthritic joint disease4MONDO:0005578EFO:0005856
common cold4MONDO:0005709EFO:0007214
influenza4MONDO:0005812EFO:0007328
pharyngitis4MONDO:0002258MONDO:0002258
migraine disorder4MONDO:0005277MONDO:0005277
osteoarthritis, knee3MONDO:0005416EFO:0004616
injury3MONDO:0021178EFO:0000546
bacterial meningitis3MONDO:0006670EFO:1000831
obesity disorder3MONDO:0011122EFO:0001073
osteoarthritis, hip3MONDO:0006629EFO:1000786
neoplasm3MONDO:0005070EFO:0000616
HIV infectious disease3MONDO:0005109EFO:0000764
malaria3MONDO:0005136EFO:0001068
plasma cell myeloma3MONDO:0009693EFO:0001378
kidney disorder3MONDO:0005240EFO:0003086
lupus nephritis3MONDO:0005556EFO:0005761
extramammary Paget disease3MONDO:0008177EFO:1000249
diabetic neuropathy3MONDO:0006626EFO:1000783
streptococcal infection3MONDO:0021680EFO:1001476
myopia3MONDO:0001384HP:0000545
nephrolithiasis3MONDO:0008171EFO:0004253
scoliosis3MONDO:0005392EFO:0004273
delirium3MONDO:0045057EFO:0009267
patent ductus arteriosus3MONDO:0011827HP:0001643
hypospadias3MONDO:0005345EFO:0004209
pemphigus3MONDO:0006594EFO:1000749
respiratory tract infectious disorder3MONDO:0024355MONDO:0024355
severe acute respiratory syndrome3MONDO:0005091MONDO:0100096
Plasmodium falciparum malaria3MONDO:0005920EFO:0007444
osteoarthritis3MONDO:0005178MONDO:0005178
multiple sclerosis3MONDO:0005301MONDO:0005301
systemic lupus erythematosus3MONDO:0007915MONDO:0007915
cleft palate2MONDO:0016064HP:0000175
hypertensive disorder2MONDO:0005044EFO:0000537
bone fracture2MONDO:0005315EFO:0003931
pulpitis2MONDO:0006937EFO:1001139
neoplasm of mature B-cells2MONDO:0004949EFO:0000096
cutaneous melanoma2MONDO:0005012EFO:0000389
lymphoma2MONDO:0005062EFO:0000574
rheumatoid arthritis2MONDO:0008383EFO:0000685
graft versus host disease2MONDO:0013730EFO:0004599
neuralgia2MONDO:0021667EFO:0005762
non-Hodgkin lymphoma2MONDO:0018908EFO:0005952
mast cell leukemia2MONDO:0020334EFO:0007359
sinusitis2MONDO:0005961EFO:0007486
mucositis2MONDO:0020579EFO:1001898
borderline personality disorder2MONDO:0001156HP:0012076
acute lymphoblastic leukemia2MONDO:0004967EFO:0000220
diffuse large B-cell lymphoma2MONDO:0018905EFO:0000403
preeclampsia2MONDO:0005081EFO:0000668
rotator cuff syndrome2MONDO:0007028EFO:1001250
non-small cell lung carcinoma2MONDO:0005233EFO:0003060
T-cell leukemia2MONDO:0005525EFO:0005592
breast neoplasm2MONDO:0021100MONDO:0007254
brain injury2MONDO:0043510MONDO:0043510
glioma2MONDO:0021042MONDO:0100342
acute myeloid leukemia2MONDO:0018874EFO:0000222
anxiety2MONDO:0011918EFO:0005230
myelodysplastic syndrome2MONDO:0018881EFO:0000198
type 1 diabetes mellitus2MONDO:0005147MONDO:0005147
kidney cancer2MONDO:0002367MONDO:0002367
leukemia2MONDO:0005059EFO:0000565
kidney neoplasm2MONDO:0021163EFO:0003865
hairy cell leukemia2MONDO:0018935EFO:1000956
tonsillitis2MONDO:0001039MONDO:0001039
follicular lymphoma2MONDO:0018906MONDO:0018906
morbid obesity1MONDO:0005139EFO:0001074
chronic myeloid leukemia1MONDO:0011996EFO:0000339
hepatitis B virus infection1MONDO:0005344EFO:0004197
Crohn disease1MONDO:0005011EFO:0000384
immune system disorder1MONDO:0005046EFO:0000540
intervertebral disk degenerative disorder1MONDO:0011385HP:0008419
B-cell chronic lymphocytic leukemia1MONDO:0004948EFO:0000095
nervous system disorder1MONDO:0005071EFO:0000618
autoimmune thrombocytopenic purpura1MONDO:0008558EFO:0007160
type 2 diabetes mellitus1MONDO:0005148MONDO:0005148
Parkinson disease1MONDO:0005180MONDO:0005180
hepatitis1MONDO:0002251HP:0012115
glycogen storage disease III1MONDO:0009291MONDO:0009291
urinary bladder neoplasm1MONDO:0004987EFO:0000294
diabetes mellitus1MONDO:0005015EFO:0000400
mesothelioma1MONDO:0005065EFO:0000588
esophageal squamous cell carcinoma1MONDO:0005580EFO:0005922
tooth disorder0MONDO:0006999EFO:1001216
glaucoma0MONDO:0005041MONDO:0005041

34 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 966.

Phase distribution

PhaseTrials
PHASE4327
Not specified224
PHASE3131
PHASE2122
PHASE195
PHASE1/PHASE227
PHASE2/PHASE324
EARLY_PHASE116

Top trials by phase / activity

NCTPhaseStatusTitle
NCT03759028PHASE4RECRUITINGSupracondylar Post-Operative Pain Study
NCT03781544PHASE4RECRUITINGEffects of Opioids and NSAIDs on Sympathetic Nervous System and Vascular Function
NCT04240626PHASE4ACTIVE_NOT_RECRUITINGMultimodal Analgesia Effect on Post Surgical Patient
NCT05076110PHASE4RECRUITINGNonopioid Pain Control Regimen After Arthroscopic Hip Procedures
NCT05488847PHASE4ACTIVE_NOT_RECRUITINGOpioid-Free Pain Protocol After Shoulder Arthroplasty
NCT05690282PHASE4ACTIVE_NOT_RECRUITINGComparing Perioperative Outcomes in Pain Control
NCT05722002PHASE4RECRUITINGComparing Analgesic Regimen Effectiveness and Safety for Surgery (CARES) Trial
NCT05878015PHASE4ENROLLING_BY_INVITATIONA Study of Intravenous Acetaminophen for Small Bowel Obstruction
NCT05919745PHASE4RECRUITINGPreemptive Ibuprofen Effects on Pain Perception Following Extraction and Bone Graft
NCT06373978PHASE4RECRUITINGNonNarcotic Pain Control in Percutaneous Needle Tenotomy of Elbow
NCT06379425PHASE4RECRUITINGImpact of Preoperative Opioid-free Multimodal Analgesia on Time to Trial of Void in Ambulatory Urogynecologic Surgeries
NCT06434233PHASE4RECRUITINGOpioid Use After Laparoscopic Salpingectomy
NCT06479122PHASE4RECRUITINGEfficacy of Acetaminophen Alone Versus Combination of Acetaminophen/Ibuprofen After Cesarean Section
NCT06505148PHASE4NOT_YET_RECRUITINGComparing the Difference in Pain Control in the Pediatric General Surgery Population: to Alternate or Combine Acetaminophen and Ibuprofen?
NCT06613178PHASE4RECRUITINGIntravenous Acetaminophen After Cardiac Surgery - Definitive Study
NCT06671002PHASE4RECRUITINGComparing Analgesic Regimen Effectiveness and Safety for Surgery for Kids Trial
NCT06950840PHASE4NOT_YET_RECRUITINGAntipyretic Treatment for Intrapartum Fever: Dipyrone vs Acetaminophen (RCT)
NCT06997016PHASE4ENROLLING_BY_INVITATIONEnhanced Recovery After Surgery (ERAS) in Live Donor Kidney Transplant Recipients
NCT07022496PHASE4RECRUITINGAssessment of Oral Caffeine Intake in Changing the Severity of Acute Migraine Attack Using VAS Score Among Patients Attending Headache and Neurology Outpatients Clinic of Ainshams University Hospitals
NCT07101445PHASE4RECRUITINGEvaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
NCT07102641PHASE4RECRUITINGPost-cesarean Analgesia: Comparing Effectiveness of Staggered v. Simultaneous Therapies
NCT07169227PHASE4NOT_YET_RECRUITINGLidocaine, Paracetamol, and Dexmedetomidine for Rocuronium Injection Pain
NCT07200544PHASE4RECRUITINGMeloxicam in Mohs Micrographic Surgery
NCT07203079PHASE4NOT_YET_RECRUITINGOral Versus Intravenous Acetaminophen in Lumbar Spine Surgery
NCT07235995PHASE4NOT_YET_RECRUITINGParacetamol and Mannitol Injection and Postoperative Delirium
NCT07440069PHASE4RECRUITINGAnalgesic Efficacy and Obstetric Effects of Tramadol, Paracetamol and Placebo in Active Labor
NCT07512297PHASE4NOT_YET_RECRUITINGPain Control During ESWL Using Non-Opioid Analgesics
NCT07536425PHASE4NOT_YET_RECRUITINGPreoperative Indomethacin and Paracetamol for Pain Management During Oocyte Retrieval in IVF Patients
NCT07539935PHASE4ACTIVE_NOT_RECRUITINGAnalgesic Effect of Superficial Cervical Plexus Block in Postoperative Neck Surgeries
NCT07567924PHASE4ACTIVE_NOT_RECRUITINGComparison Between Pregabalin and Acetaminophen for the Treatment of Post-Mastectomy Pain Syndrome
NCT07571252PHASE4NOT_YET_RECRUITINGImpact of Preemptive Analgesia on Postoperative Pain in Orthognathic Surgery
NCT07605065PHASE4NOT_YET_RECRUITINGDexamethasone Plus Metoclopramide Versus Paracetamol/NSAIDs for Primary Headache
NCT00137566PHASE4UNKNOWNThe Effect of Paracetamol in the Treatment of Non-severe Malaria in Children in Guinea-Bissau
NCT00240825PHASE4COMPLETEDAn Effectiveness and Safety Study of Acetaminophen 1000 mg and Ibuprofen 400 mg in Postoperative Dental Pain.
NCT00240864PHASE4COMPLETEDAn Effectiveness and Safety Study of Acetaminophen 1000 mg and Ibuprofen 400 mg in Postoperative Dental Pain
NCT00261560PHASE4COMPLETEDA Safety and Effectiveness Study of Acetaminophen Extended Release (3900 mg/Day) and Ibuprofen (1200 mg/Day) in the Treatment of Pain Associated With Ankle Sprains.
NCT00261586PHASE4COMPLETEDA Safety Trial to Compare Different Analgesics in Combination With Low Dose Aspirin to Study Their Bleeding Properties and Their Effects on the Stomach
NCT00267293PHASE4COMPLETEDIbuprofen Alone and in Combination With Acetaminophen for Treatment of Fever
NCT00292214PHASE4COMPLETEDComparing Intravenous and Oral Paracetamol for Cholecystectomy
NCT00297375PHASE4COMPLETEDA Study Comparing the Effectiveness and Safety of ULTRACET® (Tramadol HCl/Acetaminophen) Versus Placebo for the Treatment of Acute Pain From a Migraine Headache

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 35 clinical and 83 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

413 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
3,3’,4’,5-TETRACHLOROSALICYLANILIDEChEMBLPhase 4 (approved)PTGS1, PTGS2
ACEMETACINChEMBLPhase 4 (approved)PTGS1, PTGS2
ASPIRINChEMBLPhase 4 (approved)PTGS1, PTGS2
BROMFENACChEMBLPhase 4 (approved)PTGS1, PTGS2
CAPSAICINChEMBLPhase 4 (approved)PTGS1, PTGS2
CAPTOPRILChEMBLPhase 4 (approved)PTGS1, PTGS2
CARPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
CELECOXIBChEMBLPhase 4 (approved)PTGS1, PTGS2
CIANIDANOLChEMBLPhase 4 (approved)PTGS1, PTGS2
DEXIBUPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
DEXKETOPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
DICLOFENACChEMBLPhase 4 (approved)PTGS1, PTGS2
DIETHYLSTILBESTROLChEMBLPhase 4 (approved)PTGS1, PTGS2
DOXORUBICINChEMBLPhase 4 (approved)PTGS1, PTGS2
ESFLURBIPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
ETODOLACChEMBLPhase 4 (approved)PTGS1, PTGS2
ETORICOXIBChEMBLPhase 4 (approved)PTGS1, PTGS2
FLURBIPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
GLAFENINEChEMBLPhase 4 (approved)PTGS1, PTGS2
HEXACHLOROPHENEChEMBLPhase 4 (approved)PTGS1, PTGS2
IBUPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
INDOMETHACINChEMBLPhase 4 (approved)PTGS1, PTGS2
KETOPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
KETOROLACChEMBLPhase 4 (approved)PTGS1, PTGS2
LEVODOPAChEMBLPhase 4 (approved)PTGS1, PTGS2
LOXOPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
LUMIRACOXIBChEMBLPhase 4 (approved)PTGS1, PTGS2
MECLOFENAMIC ACIDChEMBLPhase 4 (approved)PTGS1, PTGS2
MEFENAMIC ACIDChEMBLPhase 4 (approved)PTGS1, PTGS2
MELOXICAMChEMBLPhase 4 (approved)PTGS1, PTGS2
MOFEZOLACChEMBLPhase 4 (approved)PTGS1, PTGS2
MONOBENZONEChEMBLPhase 4 (approved)PTGS1, PTGS2
NAPROXENChEMBLPhase 4 (approved)PTGS1, PTGS2
NIMESULIDEChEMBLPhase 4 (approved)PTGS1, PTGS2
OMADACYCLINEChEMBLPhase 4 (approved)PTGS1, PTGS2
OXAPROZINChEMBLPhase 4 (approved)PTGS1, PTGS2
PIROXICAMChEMBLPhase 4 (approved)PTGS1, PTGS2
PRIMAQUINEChEMBLPhase 4 (approved)PTGS1, PTGS2
RANITIDINEChEMBLPhase 4 (approved)PTGS1, PTGS2
ROFECOXIBChEMBLPhase 4 (approved)PTGS1, PTGS2
SELINEXORChEMBLPhase 4 (approved)PTGS1, PTGS2
SUPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
TEGASERODChEMBLPhase 4 (approved)PTGS1, PTGS2
TELOTRISTATChEMBLPhase 4 (approved)PTGS1, PTGS2
TOLMETINChEMBLPhase 4 (approved)PTGS1, PTGS2
TROGLITAZONEChEMBLPhase 4 (approved)PTGS1, PTGS2
VALDECOXIBChEMBLPhase 4 (approved)PTGS1, PTGS2
VORTIOXETINEChEMBLPhase 4 (approved)PTGS1, PTGS2
CURCUMINChEMBLPhase 3PTGS1, PTGS2
RESVERATROLChEMBLPhase 3PTGS1, PTGS2
CIMICOXIBChEMBLPhase 2PTGS1, PTGS2
DERACOXIBChEMBLPhase 2PTGS1, PTGS2
ENOFELASTChEMBLPhase 2PTGS1, PTGS2
FIROCOXIBChEMBLPhase 2PTGS1, PTGS2
FLUFENAMIC ACIDChEMBLPhase 2PTGS1, PTGS2
LICOFELONEChEMBLPhase 2PTGS1, PTGS2
MAVACOXIBChEMBLPhase 2PTGS1, PTGS2
MIROPROFENChEMBLPhase 2PTGS1, PTGS2
NIFLUMIC ACIDChEMBLPhase 2PTGS1, PTGS2
PHENOTHIAZINEChEMBLPhase 2PTGS1, PTGS2

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot